- Home
- VRCA vs SER Comparison
VRCA vs SER Comparison
Compare VRCA & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- SER
- Stock Information
- Founded
- VRCA 2013
- SER 2017
- Country
- VRCA United States
- SER United States
- Employees
- VRCA N/A
- SER N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- SER Health Care
- Exchange
- VRCA Nasdaq
- SER Nasdaq
- Market Cap
- VRCA 54.0M
- SER 56.5M
- IPO Year
- VRCA 2018
- SER 2018
- Fundamental
- Price
- VRCA $0.82
- SER $5.70
- Analyst Decision
- VRCA Hold
- SER Strong Buy
- Analyst Count
- VRCA 5
- SER 1
- Target Price
- VRCA $6.00
- SER $11.00
- AVG Volume (30 Days)
- VRCA 672.3K
- SER 15.6K
- Earning Date
- VRCA 08-13-2025
- SER 08-08-2025
- Dividend Yield
- VRCA N/A
- SER N/A
- EPS Growth
- VRCA N/A
- SER N/A
- EPS
- VRCA N/A
- SER N/A
- Revenue
- VRCA $7,179,000.00
- SER $51,000.00
- Revenue This Year
- VRCA $171.87
- SER N/A
- Revenue Next Year
- VRCA $71.38
- SER N/A
- P/E Ratio
- VRCA N/A
- SER N/A
- Revenue Growth
- VRCA N/A
- SER N/A
- 52 Week Low
- VRCA $0.38
- SER $3.81
- 52 Week High
- VRCA $8.98
- SER $11.57
- Technical
- Relative Strength Index (RSI)
- VRCA 68.47
- SER 38.22
- Support Level
- VRCA $0.52
- SER $5.27
- Resistance Level
- VRCA $0.67
- SER $6.36
- Average True Range (ATR)
- VRCA 0.08
- SER 0.42
- MACD
- VRCA 0.03
- SER -0.08
- Stochastic Oscillator
- VRCA 70.47
- SER 6.98
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.